Affimed N.V. (AFMD)’s Financial Results Comparing With Esperion Therapeutics Inc. (NASDAQ:ESPR)

We are comparing Affimed N.V. (NASDAQ:AFMD) and Esperion Therapeutics Inc. (NASDAQ:ESPR) on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Affimed N.V. N/A 0.00 N/A -0.70 0.00
Esperion Therapeutics Inc. N/A 0.00 201.81M -6.75 0.00

Table 1 demonstrates Affimed N.V. and Esperion Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Affimed N.V. 0.00% -82.1% -63.5%
Esperion Therapeutics Inc. 0.00% -91.3% -77.2%

Risk and Volatility

Affimed N.V.’s current beta is 3.34 and it happens to be 234.00% more volatile than Standard & Poor’s 500. Esperion Therapeutics Inc. on the other hand, has 2.15 beta which makes it 115.00% more volatile compared to Standard & Poor’s 500.


Affimed N.V.’s Current Ratio is 3.7 while its Quick Ratio is 3.6. On the competitive side is, Esperion Therapeutics Inc. which has a 4 Current Ratio and a 4 Quick Ratio. Esperion Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Affimed N.V.

Analyst Ratings

Affimed N.V. and Esperion Therapeutics Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Affimed N.V. 0 0 0 0.00
Esperion Therapeutics Inc. 1 3 4 2.50

On the other hand, Esperion Therapeutics Inc.’s potential upside is 35.85% and its average price target is $67.75.

Institutional & Insider Ownership

Institutional investors held 41.9% of Affimed N.V. shares and 0% of Esperion Therapeutics Inc. shares. 12.63% are Affimed N.V.’s share held by insiders. On the other hand, insiders held about 2.2% of Esperion Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Affimed N.V. 5.8% 6.41% -18.34% -40.65% 56.99% 17.36%
Esperion Therapeutics Inc. -1.37% -0.52% -11.78% -7.08% -39.96% 0.46%

For the past year Affimed N.V.’s stock price has bigger growth than Esperion Therapeutics Inc.


On 5 of the 7 factors Affimed N.V. beats Esperion Therapeutics Inc.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.